Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 53,955

Document Document Title
WO/2023/208143A1
The present application relates to a pyrazole-substituted cyclopentanol ester derivative and use thereof, and in particular to a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.  
WO/2023/211213A1
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transport and injection ability, light-emitting abilit...  
WO/2023/207556A1
The present invention provides a compound as a PRMT5-MTA inhibitor, which is a compound represented by formula (A) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate ...  
WO/2023/209028A1
The invention relates to sulphonyl benzene derivatives, in particular to fluorinated sulphonyl benzene derivatives. It is provided a compound of formula (I) or general formula (IA) wherein X is fluorine; A is either O or NH; B is an amin...  
WO/2023/207284A1
Disclosed are piperazine derivatives and pharmaceutically acceptable salts thereof that inhibit the Poly (ADP-ribose) polymerase (PARP) family of enzymes. Also disclosed is the use of these compounds or pharmaceutically acceptable salts ...  
WO/2023/206665A1
The present invention relates to a process for unprotected asymmetric preparation of nicotine. Specifically, optically pure nicotine is prepared from a nicotinate as the starting material through four reactions, wherein the preparation o...  
WO/2023/211990A1
Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-ga...  
WO/2023/207960A1
The present invention relates to a substituted fused pyrimidine-based derivative, a method for preparing same, and pharmaceutical use of a pharmaceutical composition comprising the derivative. Specifically, the present invention relates ...  
WO/2023/207875A1
Provided herein are CDK inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provide herein is a method of their use for treating, preventing, or ameliorating a chemotherapy-induced gastrointestinal ...  
WO/2023/211238A1
The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus is useful as a therapeutic agent for EGFR-related ...  
WO/2023/201423A1
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...  
WO/2023/205272A1
The present application provides compounds and methods for treating various diseases such as malaria and cancer.  
WO/2023/201421A1
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...  
WO/2023/202655A1
Provided herein are a compound of Formula (I), a pharmaceutical composition comprising said compound, and method of use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpress...  
WO/2023/205173A1
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...  
WO/2023/202582A1
A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...  
WO/2023/205465A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...  
WO/2023/201780A1
Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...  
WO/2023/205226A1
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting mutant KIT prote...  
WO/2023/205219A1
Provided herein are E2 binding PROTACS and uses thereof.  
WO/2023/205164A1
The present disclosure encompasses processes for the preparation of (S)-Finerenone.  
WO/2023/203162A1
The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relate...  
WO/2023/205369A1
A pharmacotherapeutic protocol enhancing neuro-restoration in the human brain for patients suffering with brain injuries and diseases, wherein the protocol comprises treating the patient with a combinatorial pharmacological composition c...  
WO/2023/202336A1
Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and/or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of dr...  
WO/2023/205463A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...  
WO/2023/202545A1
Provided in the present invention is the use of a diphenyl pyrazole compound represented by general formula (I) or a pesticidally acceptable salt thereof as a herbicide synergist. The compound is an inhibitor targeting GSTs in farmland w...  
WO/2023/205778A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...  
WO/2023/205468A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...  
WO/2023/205074A1
The present invention relates to new synthetic routes of synthesizing adagrasib. The invention also provides intermediates used in the provided synthetic routes.  
WO/2023/205807A2
The present disclosure relates to 1,4,5 -substituted 1,2,3-triazoles useful as modulators of pregnane X receptor (PXR) and in the treatment of disorders associated with PXR dysfunction (e.g, disorders of uncontrolled cellular proliferati...  
WO/2023/198180A1
The present invention relates to a novel compound of general formula (A) capable of inhibiting and inducing degradation of EGFR, and a pharmaceutical composition comprising the compound, which can be used for treating diseases associated...  
WO/2023/199345A1
The present invention relates to novel solid-state forms of Voxelotor of formula-1 and their preparation methods thereof. The Voxelotor of formula-1 is represented by the following structural formula. The present invention also related t...  
WO/2023/201282A1
Provided herein are compounds having the formula I for treating, preventing or managing cancer. Also provided are pharmaceutical compositions comprising the compounds and methods of use of the compounds and compositions. In certain embod...  
WO/2023/199091A1
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.  
WO/2023/193760A1
This disclosure relates to GSPT1 degrader compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds or salts, and methods of making and using the compounds or salts for the treatment o...  
WO/2023/195530A1
The present invention provides a compound showing coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. A compound represented by formula (I) [in...  
WO/2023/196985A1
Disclosed herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A and A' are each independently selected from the group consisting of: (a1), (a2), (a3), (4) and (a5) and B, B', X and Y have the meani...  
WO/2023/196512A1
Disclosed are compounds of formula I, formula I-1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof that are useful for modulating or degrading bromodomain (e.g., BRD4).  
WO/2023/193733A1
The present disclosure relates to the field of medicine. Specifically, provided in the present disclosure are a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, and a pharmaceutically acceptable sa...  
WO/2023/194065A1
A process is described for preparing compounds of the class of sterically hindered alkoxyamines, which process comprises the step of alkylating a sterically hindered nitroxyl compound to the corresponding sterically hindered alkoxyamine ...  
WO/2023/194895A1
This invention relates to novel compounds which are inhibitors of APOL1, pharmaceutical compositions containing the compounds, processes for their preparation, and uses thereof in therapy for the treatment of kidney diseases and sepsis.  
WO/2023/195529A1
The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...  
WO/2023/196283A1
The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.  
WO/2023/196527A2
Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, str...  
WO/2023/195773A1
The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative represented by chemical formula (I) and a pharmaceutical composition including same effectively suppress HER2 activity, and thus are usef...  
WO/2023/195026A1
The present invention relates to novel highly efficient and economic process for large-scale production of Apalutamide. The present invention also relates to novel process that form highly pure Apalutamide through a novel intermediate. T...  
WO/2023/193795A1
The present invention relates to a compound targeting focal adhesion kinase and a preparation method for and an application of the compound. The compound targeting focal adhesion kinase of the present invention has the following general ...  
WO/2023/196958A2
Described herein are targeted azonafide compositions comprising one or more cytotoxic azonafide-based compounds and methods of using the compositions to deliver a cytotoxic compound to a tumor and/or cancer cell, as well as methods of us...  
WO/2023/196629A1
The invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof; wherein Ra and Rb are both -CH3 or Ra and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2- bridging moiety; A is -CH2- or -C(=O)-; T i...  
WO/2023/196614A1
The disclosure provides compounds of Formulas (I), (I-2), (I-3), (I-4), (I-5), (II), (II-2), (II-3), (II-4), and (II-5) and pharmaceutically acceptable salts thereof. Also provided are compositions and methods of using the compounds, e.g...  

Matches 551 - 600 out of 53,955